Sonja Korhonen

Ms. Sonja Korhonen

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 October 2022 in Nutrients
Verified
Journal Article
Open access
PDF file
SCSusanne Csader
Susanne Csader
SKSonja Korhonen
Sonja Korhonen
Kai KaarnirantaKai Kaarniranta
Kai Kaarniranta
USUrsula Schwab
Ursula Schwab
Purpose: Age-related macular degeneration (AMD) is a neurodegenerative ophthalmic disease. The purpose of this systematic review (SR) and meta-analysis was to evaluate if dietary supplementation alone or in combinations might delay the progression of any of the stages of AMD. Methods: A SR and meta-analysis identifying cohort studies and randomized controlled trials (RCTs) evaluating the effect of supplements in patients diagnosed with AMD. PubMed, Scopus, Web of Science, CINAHL, and Cochrane were searched through 8th October 2021. Results: Twenty studies, examining 5634 participants ranging from 55 to 80 years, were included in the SR. Eight studies were selected for meta-analysis (414 and 216 subjects in the intervention and control groups). Lutein and zeaxanthin plus n-3 long-chain polyunsaturated fatty acids (n-3 LC-PUFA) supplementation showed significant improvements in best-corrected visual acuity (BCVA) (SMD: −1.99, 95% CI: −3.33, −0.65) compared to the control group. Multifocal electroretinogram results (mfERG) were significantly improved overall (SMD: 4.59, 95% CI: 1.75, 7.43) after lutein plus zeaxanthin supplementation. Conclusions: Combinations of lutein and zeaxanthin with n-3 LC-PUFA might be beneficial in preventing AMD progression and deterioration of visual function. Our results encourage initiating further studies with combinations of n-3 LC-PUFA, lutein, and zeaxanthin especially in early AMD patients.

4 October 2024 in Molecular Therapy Nucleic Acids
Verified
Journal Article
Open access
SKSonja Korhonen
Sonja Korhonen
KSKatja Stenberg
Katja Stenberg
USUmair Seemab
Umair Seemab
PBPiia Bartos
Piia Bartos
KMKatariina Mäkiniemi
Katariina Mäkiniemi
ASAstrid Subrizi
Astrid Subrizi
Ocular diseases create a significant economic burden and decrease in quality of life worldwide. Drugs and carrier molecules that penetrate ocular tissues after intravenous administration are needed for more efficient and patient-friendly treatment of ocular diseases. Here, ocular barrier-penetrating aptamers were selected through the utilization of in vivo SELEX and intravenous injection in rats. Three aptamers—Apt1, Apt2, and Apt5—were chosen based on their specific accumulation in vascularized ocular tissues and further characterized for their in vivo biodistribution using quantitative reverse-transcription PCR (RT-qPCR). A statistically significant difference between ΔCt values of ocular and control tissues with Apt2 (p < 0.0001) and Apt5 (p < 0.0001) was observed. Interestingly, Apt1 was the most abundant aptamer in the sequencing pool, but it did not show a statistically significant difference in in vivo biodistribution between ocular and control tissues. Overall, this study established a functional in vivo SELEX method for discovering ocular tissue targeting aptamers.

12 April 2022 in Acta Oncologica
Verified
Journal Article
Closed access
RLRiikka-Leena Leskelä
Riikka-Leena Leskelä
EPEmmi Peltonen
Emmi Peltonen
IHIra ira Haavisto
Ira ira Haavisto
FHFredrik Herse
Fredrik Herse
SKSonja Korhonen
Sonja Korhonen
JKJussi Koivunen
Jussi Koivunen
Non-small cell lung cancer (NSCLC) is a leading cause of cancer mortality in the Western world. However, emerging treatment options and more patients directed to active treatments might improve the...

26 July 2024 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Open access
SKSonja Korhonen
Sonja Korhonen
SBStef Bosch
Stef Bosch
AEAntero Erkinheimo
Antero Erkinheimo
TLTatu Lajunen
Tatu Lajunen
KRKirsi Rilla
Kirsi Rilla
MRMika Reinisalo
Mika Reinisalo
Retinoblastoma is the most common pediatric intraocular malignant tumor affecting 1:15 000-1:20 000 live births. Even though the survival rate in developed countries is over 90 %, more efficient treatment options are needed for better vision salvage and reduction of the adverse effects. Therefore, we investigated fluorescein-labeled PL3 peptide targeting properties towards the Y79 retinoblastoma cell line in vitro. Through the application of cellular imaging and flow cytometry techniques, the PL3 peptide exhibited a rapid and specific internalization within Y79 cells, with subsequent translocation to the cell nuclei, showcasing notable accumulation in the nucleoli. This phenomenon was not present in other investigated cell lines and was not observable with similarly charged and length control peptide. However, the exact mechanism behind this Y79 cell line-specific nuclear and nucleolar targeting pattern remains elusive. In the future, this targeting process could facilitate specific treatment modalities of retinoblastoma with PL3 peptide-coupled drug delivery technologies.

25 September 2026 in Small Structures
Verified
Journal Article
Open access
PDF file
AKAnna Klose
Anna Klose
ZGZahra Gounani
Zahra Gounani
Sergei RaikSergei Raik
Sergei Raik
AKArtturi Koivuniemi
Artturi Koivuniemi
SKSonja Korhonen
Sonja Korhonen
TLTimo J Laaksonen
Timo J Laaksonen
DNA origami nanoparticles (DONs) are attractive nanocarriers of controllable size, shape, and addressability that have potential for treating eye diseases by overcoming ocular barriers. However, suboptimal physiological stability and poor cell uptake due to the negative charge may limit their use. Previous reports show that electrostatic complexation of DONs with cationic PEG‐oligolysine block copolymers like PEG5K‐K10 can improve structural integrity and promote cell internalization. Here, we investigated a dual approach of PEG5K‐K10 coatings and PL3‐targeting peptides to improve uptake of 24‐helix bundle (24HB) DONs into Y‐79 retinoblastoma cells. Uptake studies revealed that PEG5K‐K10 was essential for DON uptake in Y‐79 cells, as uptake only occurred upon exceeding a distinct PEG5K‐K10 amount. Longer exposure times or increased polymer amounts improved cell association. However, no beneficial effect of PL3 was observed. While free PEG5K‐K10 reduced cell viability at higher concentrations (IC 50 36.8 µM), coated DONs were well‐tolerated. Furthermore, single particle tracking in ex vivo porcine eyes revealed comparable vitreal mobility for uncoated and coated 24HB, with a slight decrease at higher coating amounts. Our findings highlight that PEG5K‐K10 can enhance ocular cell uptake without limiting nanoparticle diffusivity in the vitreous and support further optimization of DONs for ocular drug delivery.

10 June 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
AKAnna Klose
Anna Klose
ZGZahra Gounani
Zahra Gounani
Sergei RaikSergei Raik
Sergei Raik
AKArtturi Koivuniemi
Artturi Koivuniemi
SKSonja Korhonen
Sonja Korhonen
TLTimo J Laaksonen
Timo J Laaksonen
DNA origami nanoparticles (DONs) are attractive nanocarriers of controllable size, shape and addressability that have potential for treating eye diseases by overcoming ocular barriers. However, suboptimal physiological stability and poor cell uptake due to the negative charge may limit their use. Previous reports show that electrostatic complexation of DONs with cationic PEG-oligolysine block-copolymers like PEG5K-K10 can improve structural integrity and promote cell internalization. Here, we investigated a dual approach of PEG5K-K10 coatings and PL3 targeting peptides to improve uptake of 24-helix bundle (24HB) DONs into Y-79 retinoblastoma cells. Uptake studies revealed that PEG5K-K10 was essential for DON uptake in Y-79 cells, as uptake only occurred upon exceeding a distinct PEG5K-K10 amount. Longer exposure times or increased polymer amounts improved cell association. However, no beneficial effect of PL3 was observed. While free PEG5K-K10 reduced cell viability at higher concentrations (IC 50 36.8 µM), coated DONs were well-tolerated. Furthermore, single particle tracking in ex vivo porcine eyes revealed comparable vitreal mobility for uncoated and coated 24HB, with a slight decrease at higher coating amounts. Our findings highlight that PEG5K-K10 can enhance ocular cell uptake without limiting nanoparticle diffusivity in the vitreous, and support further optimization of DONs for ocular drug delivery.